Location History:
- Seoul, KR (1999 - 2000)
- Daejeon, KR (2000 - 2001)
Company Filing History:
Years Active: 1999-2001
Title: Innovations by Seung Un Kim in Cholesterol Biosynthesis Inhibition
Introduction
Seung Un Kim is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of cholesterol biosynthesis inhibitors, holding a total of 6 patents. His work focuses on developing compounds that can effectively treat conditions related to high cholesterol levels.
Latest Patents
Among his latest patents, Seung Un Kim has developed a cholesterol biosynthesis inhibitor that specifically targets sterol 14-reductase, an enzyme involved in the distal pathway of cholesterol biosynthesis. This invention includes a compound that can be used for treating hypercholesterolemia or hyperlipidemia. The inhibitor is derived from an extract obtained through solvent extraction or partitioning with an organic solvent. The active ingredients in this extract include 7,8,13,13α-tetrahydrocoridaline or its derivatives, which play a crucial role in inhibiting the enzyme responsible for cholesterol biosynthesis.
Another significant patent by Kim involves 13,13A-Didehydroberbine derivatives, which also serve as cholesterol biosynthesis inhibitors. Similar to his previous invention, this compound is derived from Corydalis Turtschaninowii Besser and aims to treat hypercholesterolemia or hyperlipidemia by inhibiting the same enzyme.
Career Highlights
Seung Un Kim has worked with prominent companies such as Hanwha Corporation and Hanwha Chemical Corporation. His experience in these organizations has contributed to his expertise in the field of cholesterol biosynthesis and related innovations.
Collaborations
Throughout his career, Kim has collaborated with notable colleagues, including Jung Ho Kim and Tae Neung Jhong. These partnerships have likely enhanced his research and development efforts in the area of cholesterol biosynthesis inhibitors.
Conclusion
Seung Un Kim's innovative work in cholesterol biosynthesis inhibitors showcases his dedication to addressing health issues related to cholesterol. His patents reflect a commitment to advancing medical treatments and improving patient outcomes.